ArticleScientific reports2025
Protective and therapeutic potentials of Trichinella spiralis larval antigen in murine induced colitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- S100a4 mediated peritoneal B1 lymphocytes play a critical role in host protection against helminth infection.Cell communication and signaling : CCS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intolerable side effects and clinical limitations of current conventional therapies for inflammatory bowel diseases (IBDs), there is a pressing need for alternative treatment options. Helminthes adapt immune responses of their hosts to reduce immune-mediated IBDs. The identification of the mechanism responsible for this beneficial effect on IBDs will provide another feasible approach to treating these diseases. The study was designed to investigate the possible protective and therapeutic role of Trichinella spiralis (T. spiralis) crude larval antigen extract in mice challenged with 2,4,6-trinitrobenzene sulfonic acid (TNBS) to induce colitis. Colitis was induced by intra-colonic instillation of TNBS (5 mg/ml in 50% ethanol), preceded or followed by intra-peritoneal (i.p.) administration of a single dose of T. spiralis crude larval antigen extract (100 µg/mouse). Colonic damage was assessed macroscopically and microscopically, and the expression of myeloperoxidase (MPO) was evaluated by immunohistochemistry. Colonic interleukin-10 (IL-10) and serum nitric oxide (NO) levels were also measured. Administration of T. spiralis crude larval antigen extract before induction of colitis reduced colitis severity as demonstrated by reduced colon weight-to-length ratio, improved macroscopic and microscopic scores, increased colonic IL-10 expression, and diminished colonic MPO protein expression. Moreover, there was a significant negative correlation between serum NO and colonic IL-10 levels. In addition, the preventive potential of T. spiralis crude larval antigen extract against TNBS-induced colitis was more prominent than its therapeutic effect. These findings support the hypothesis that T. spiralis has both prophylactic and therapeutic potential in inflammatory bowel diseases, which may be via an increase in IL-10 with predominance of its prophylactic role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.